

C. LeVisage, et al.  
 U.S.S.N.: 09/975,565  
 Page 2


**Amendments To The Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1. (Currently Amended) A pharmaceutical composition comprising:  
 a microparticle having an mean particle size of between about 0.5 1.0  $\mu\text{m}$  and about 100  $\mu\text{m}$ , said microparticle comprising:

a polymeric support material in which a substance can be dispersed, wherein the support material comprises at least about 50% w/w of at least one homopolymer with a repeat unit according to Formula (I):



wherein

$R_1$  represents a  $\text{C}_1\text{--C}_6$  alkyl group or a group  $(\text{CH}_2)_m\text{---COOR}_3$  wherein  $m$  is an integer from 1 to 5 and  $R_3$  is a  $\text{C}_1\text{--C}_6$  alkyl group,  $R_1$  and  $R_3$  being the same or different;

$R_2$  represents a  $\text{C}_1\text{--C}_6$  alkyl group the same or different from  $R_1$  and  $R_3$ ;

$n$  is an integer from 1 to 5; and

at least one therapeutic agent that is encapsulated or dispersed in the polymeric support material of the microparticle.

2. (Original) A pharmaceutical composition according to claim 1 wherein:

$R_1$  and  $R_2$  are independently chosen  $\text{C}_1\text{--C}_6$  alkyl groups; and

$n$  is 1.

3. (Original) A pharmaceutical composition according to claim 1 wherein:

C. LeVisage, et al.  
U.S.S.N.: 09/975,565  
Page 3

the stated homopolymer comprising repeat units according to Formula (I) wherein  $R_1$  and  $R_2$  are ethyl groups; and  
 $n = 1$ .

4. (Original) A pharmaceutical composition according to claim 3, wherein the composition being obtained by a single emulsification process.

5. (Currently Amended) A pharmaceutical composition according to any one of claims 1 to 4 wherein the support material comprises:  
from about 90 to about 99.5% by weight of a homopolymer as defined in claim 1; and  
from about 0.5 to about 10% by weight of a polymer additive.

6. (Original) A pharmaceutical composition according to claim 5 wherein the polymer additive comprises at least one of polyethyleneoxide, polyvinylalcohol, polyvinylpyrrolidone, poly(N-2-hydroxypropyl methacrylamide), polyhydroxyethylmethacrylate, hydrophilic poly(aminoacid) such as polylysine or polysaccharide.

7. (Currently Amended) A pharmaceutical composition according to claim 5 wherein the polymer additive is a polyvinylalcohol.

8. (Currently Amended) A pharmaceutical composition according to claim 1 wherein the dispersed substance is hydrophobic.

9. (Currently Amended) A pharmaceutical composition according to claim 1 wherein the dispersed substance is a therapeutic agent that requires a solvation vehicle for administration.

10. (Currently Amended) A pharmaceutical composition according to claim 1 wherein the dispersed substance is hydrophylic.

C. LeVisage, et al.  
U.S.S.N.: 09/975,565  
Page 4

11. (Currently Amended) A pharmaceutical composition according to claim 1, wherein the dispersed substance is a therapeutic agent.

12. (Withdrawn) A pharmaceutical composition according to claim 1, wherein the dispersed substance is a peptide or polypeptide.

13. (Withdrawn) A pharmaceutical composition according to claim 1 wherein the dispersed substance is a protein.

14. (Currently Amended) A pharmaceutical composition according to any one of claim 1 wherein the dispersed substance is a bioactive molecule such as a drug, a therapeutic agent, an anticancer agent, a gene therapy agent, a plasmid DNA, a protein, an enzyme, a peptide, a radionuclide, a protein inhibitor, an analgesic, an anti-inflammatory agent, an antibiotic, an antiviral agent, an antineoplastic agent, a pyrimidine, purine or folic acid analog, a cytotoxic agent, an immunomodulator, a hormone, an antibody or a painkiller.

15. (Currently Amended) The pharmaceutical composition of Claim 14 wherein the pyrimidine analog is fluorouracil (5-FU).

16. (Currently Amended) A pharmaceutical composition according to claim 1 wherein the dispersed substance is a bioactive molecule such as an anticancer agent or a gene therapy agent.

17. (Currently Amended) A pharmaceutical composition according to claims 1 wherein the dispersed substance is a therapeutic agent for treating or reducing the severity of a urological disease or disorder.

C. LeVisage, et al.  
U.S.S.N.: 09/975,565  
Page 5

18. (Currently Amended) A pharmaceutical composition according to claim 1 wherein the dispersed substance is a therapeutic agent for bladder cancer.
19. (Currently Amended) A pharmaceutical composition according to any one of claim 1, wherein the dispersed substance is a taxane.
20. (Original) A pharmaceutical composition according to claim 19, wherein the taxane is paclitaxel, docetaxel (Taxoterc®) or taxol®.
- 21-36. (Cancelled).
37. (Currently Amended) A method for treating a urological disease or disorder comprising:  
administering intravesically a microparticle having a mean particle size of between about 1.0  $\mu\text{m}$  and 100  $\mu\text{m}$  with one or more encapsulated therapeutic agents to the lumen of the bladder;  
contacting the particles to the surface of the mucosa,  
releasing the encapsulated therapeutic agent in a controlled manner to treat the urological disease or disorder.
38. (Original) A method according to claim 37 wherein the microparticle comprises a poly(methylidene malonate 2.1.2) polymer support material.
39. (Original) A method according to claim 37 wherein the urological disorder is a cancer and the microparticle encapsulated therapeutic agent is an anticancer agent.
40. (Currently Amended) A method according to claim 37 wherein the anticancer agent is a taxane.

C. LeVisage, et al.  
U.S.S.N.: 09/975,565  
Page 6

41. (Original) A method according to any to claim 40 wherein the taxane is paclitaxel, docetaxel (Taxotere®) or taxol®.

42. (Currently Amended) A method according to claim 37, wherein microparticles with encapsulated paclitaxel are used for intravesical chemotherapy of bladder cancer.

43-51. (Cancelled).

52. (Previously Presented) The pharmaceutical composition of claim 1, wherein the microparticle has a mean particle size of between about 1.0  $\mu\text{m}$  and 20  $\mu\text{m}$ .

53. (New) The method of claim 37, wherein the microparticle has a mean particle size of between about 1.0  $\mu\text{m}$  and 20  $\mu\text{m}$ .